IGF1 and adenoma: In patients who are SSA-resistant and therefore have persistently high levels of GH and IGF-I produced by an aggressive type of adenoma, it is conceivable that the dose of PEGV (regardless of whether it is given alone or with an SSA) will have to be periodically increased over time to control rising GH production.